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Conclusions. Bevacizumab plus irinotecan in recurrent HGA improves responses, PFS and OS compared with historical data with
low toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.123
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Introduction. Clival chordomas are a rare, locally destructive and slow growing bone tumors that arise from vestiges of the noto-
chord. In adults, about 30% of chordomas occur at the base of the skull. Clival chordomas have a high rate of recurrence and have
rarely been reported to metastasize, this feature and the difﬁculty to achieve tumoral complete resection makes local progression
the most common cause of death. Case description. A 54-year old Caucasian man presented a progressive visual loss of the left
eye during one year. MRI reported a sellar and suprasellar mass of 23mm×24mm×27mm in intimate contact with the optic
chiasm and the third ventricle ﬂoor that deformes the anterior midbrain. Intraoperative exploration and pathological ﬁndings
revealed a clival chordoma. The patient underwent neurosurgery for the ﬁrst time on April 2010. On April 2011 he underwent
surgery again with partial resection because we found a suprasellar relapse of about 29mm×32mm×38mm and radiotherapy
with proton beam therapy was performed as adyuvant treatment on august 2011 in Switzerland. On February 2012 he presented
some behavioral and cognitive disorders and the MRI showed a bilateral hippocampal signal alterations that were ﬁnally diag-
nosed as radionecrosis, a side effect of the proton therapy. The symptoms were resolved with high doses of corticosteroids and
neurological and neuropsychological assessment was made too.
Conclusions. Proton beam therapy is an effective treatment for the local control of clival chordomas, especially for those patients
with small tumors. Despite successful control of these tumors, side effects such radiation necrosis are still a concern.
http://dx.doi.org/10.1016/j.rpor.2013.03.124
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Objectives. This retrospective analysis was performed to determinate the efﬁcacy, safety and feasibility of concurrent
radiochemotherapy (CRCT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with
malignant gliomas.
Methods. From July 2002 to August 2012, 96 patients with pathologically conﬁrmed malignant glioma were included in this
retrospective analysis. Median age was 62 years (range 27–80 years). Gender: male 61.5%, female 38.5%. The main tumor locations
were frontal or temporal lobe in 59.4% of cases. Preoperative ECOG: 0–1 for 88.5% of the patients. All but 3 patients (96.9%)
underwent surgery (complete resection in 57.3%) and 71.9% of the patients received treatmentwith corticosteroids. CRCT:median
dose of 60Gy (range 30–60Gy) in daily fractions of 2Gy, 5 days per week, for 6 week combined with TMZ (75mg/m2) per day.
Adjuvant chemotherapy: TMZ (150–200mg/m2) up to a median number of 6 (range 0–20) courses.
Results. With a median of follow-up of 43.5 months (range 8–128 months), median survival time was of 10.5 months with actuarial
1 and 2 years overall survival rates of 47.3% and 16.7% respectively. CCRT resulted in grade 3/4 hematologic toxicity in 2.1% of
patients. No cases of grade 5 toxicity were observed. Univariate analysis revelled that the signiﬁcant prognostic factors for overall
survival were: ECOG performance status 0–1 (p<0.00001), age at diagnoses below 60 years (p<0.033), complete tumor resection
(p<0.02), total dose of 60Gy (p<0.0001), concomitant TMZ (p<0.003), adjuvant TMZ (p<0.0001) and absence of corticosteroids
intake (p<0.025).
Conclusion. Combination of TMZ and radiotherapy for newly diagnosed malignant gliomas resulted in a clinically meaningful
and statistically signiﬁcant survival beneﬁt with minimal additional toxicity. Our results were similar to those reported in the
literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.125
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Introduction. Cranio-Spinal Irradiation (CSI) is technically very challenging, historically ﬁeld edge matching is needed because of
the mechanical limitations of standard linear accelerators.
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Purpose/objective. The purpose of this study is to assess the Volumetric Arc Therapy (VMAT) as a competitive technique for
Cranio-Spinal Irradiation (CSI) compared to the conventional 3D Conformal Radiotherapy (3D-CRT) technique.
Materials and methods. Two patients were planned for CSI with both 3D-CRT and RapidArc® (Varian Medical Systems VMAT
solution). Both patients were treated in the prone position. Plans were generated using Varian Eclipse Treatment Planning System
(TPS) and delivered by a Varian Clinac DHX with MLC120 and on-board imager for daily on-line image guidance. Dosimetric
veriﬁcation was performed with PTW Octavius and Sun Nuclear ArcCheck phantoms.
Results. The RapidArc® CSI plans were able to achieve similar or improved OAR sparing when compared to 3D-CRT. RapidArc®
plans were able to decrease the maximum dose to all of the relevant OARs. However, for lungs and bowel, the mean doses were
elevated due to the increased number of beam angles. Also RapidArc® plans resulted in a better dose coverage and homogeneity
in the target volume. A possible 3mm shift had only a minor effect on the dose distribution of the RapidArc® treatment whereas
with the 3D-CRT the shift would result in an unacceptable error (30–40%) of the calculated dose.
Conclusions. The dosimetric results indicate that RapidArc® is an advantageous alternative for CSI. The “low dose bath effect”
remains a controversial issue in all IMRT treatments, especially in the paediatric population. With the RapidArc® technique only
a treatment plan is required to deliver the total treatment dose, eliminating the need for ﬁeld matching techniques. Moreover,
the resulting dose distribution is also less volatile for technical uncertainties of the treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.126
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Introduction. Glioblastoma (GB) is the most common and malignant brain tumour in adults. Extensive surgical resection followed
by radio-chemotherapy is the current standard treatment. When biopsy is the only surgical procedure the prognostic is worse.
Age and KPS (Karnofsky Performance Status) are the most important clinical prognostic factors. Elderly patients (>70 years) are
often excluded from trials and their treatment is controversial. The aim of this study is to asses the outcome of GB patients with
biopsy-only surgical procedure and show the differences between patients younger and older than 70 years.
Material and methods. We reviewed 102 of 298 patients (34.2%) treated underwent biopsy in our hospital between January 2000
and December 2011, prospectively included in our date base. There were 58 males (57%). Median age was 60 years and median
KPS 70. Twenty-one elderly patients (20.6%, range: 71–81) and 81 younger patients (79.4%, range: 24–70). Statistical methods: All
calculations were performed by SPSS 18.0 version; p-values of <0.05 was considered signiﬁcant.
Results. Thirty-nine patients (38.2%) received no further treatment after biopsy. The most frequent causes for withholding treat-
ment were a low KPS (92.3% of untreated patients had a KPS<70 (p<0.0001)). Seventeen of the 21 elderly patients had a KPS<70
(80.9%). Furthermore, 52% of elderly patients received no adjuvant treatment (11/21).
Conclusions. 1/3 of patients with GB undergo a biopsy as the only surgical procedure and one out of three patients were not treated
after biopsy, rising to 50% in elderly patients. The main associated factor with no treatment was lower KPS, frequently viewed
in elderly patients (80% of elderly patients had a KPS<70).
http://dx.doi.org/10.1016/j.rpor.2013.03.127
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Purpose. The objective is to evaluate age, survival, time to tumor progression, therapy, and the effect of treatment at the time of
progression in patients with anaplastic astrocytoma, who had been treated with radiotherapy and concomitant temozolamide.
Patients and methods. Between January 2007 and December 2012, 22 patients (12 male, 10 female and median age 49 years) with
highly anaplastic astrocytomas were diagnosed in our hospital. According to any of several protocols, we treated 18 patients with
radiotherapy and concomitant temozolomide. Eleven of them underwent surgery. Three patients were treated with exclusive
radiotherapy with palliative intention. There was a patient who died from cardiovascular disease.
Results. The overall median survival of all patients was projected as 22 months (range 8–68 months). Five patients had a ﬁrst
relapse and the median time to ﬁrst tumor progression was 13 months (range 1–24 months). The median survival time measured
after the ﬁrst progression was 11 months (range 1–24 months). The eleven patients who were operated had a median survival
of 22 months and not operated with RTCT treatment of 13.5 months. Progression-free survival (PFS) at 6 months, the primary
protocol end point, was 100% and PFS at 12 months was 89%. The 6, 12, 24 and 60 months survival rates were 100%, 82.3%, 47%
